Where biology and engineering meet.
Photo by Towfiqu barbhuiya on Pexels
The FDA has approved the Autus Size-Adjustable Valve, a pediatric pulmonary heart valve that can be expanded after surgery with a balloon catheter. It could spare children with congenital heart defects from repeat open-heart surgeries.
Photo by Nutrisense Inc on Pexels
Eight continuous glucose monitors, one head-to-head: Dexcom's 15-day G7 and $99 OTC Stelo, Abbott's Lingo, Rio and recalled Libre 3 Plus, Senseonics' year-long implant, and Medtronic's two Simplera sensors. We compare wear time, accuracy, warm-up, alarms and ecosystem lock-in to work out which sensor suits which user.
Photo by Nutrisense Inc on Pexels
Dexcom's longest-wearing sensor stretches to 15.5 days with a marginally improved 8.0% MARD, but a disclosed 73.9% completion rate and no published pricing leave real questions about day-to-day value.
Photo by Nutrisense Inc on Pexels
Abbott's FreeStyle Libre 3 Plus is a capable real-time CGM, but the specific sensor models covered by the FDA's Class I recall are not safe to wear — falsely low readings have been tied to hundreds of serious injuries and several deaths. Check your serial number, stop using affected sensors and request a free replacement.
Photo by Margerretta on Pexels
The first CGM designed to last a full year on one implanted sensor is a genuinely meaningful step for people tired of weekly adhesive patches — but with no pricing, accuracy figures or availability detail beyond Sweden, this is a promising launch we can't fully grade yet.
Photo by Sarah Blocksidge on Pexels
Dexcom's prescription-free Stelo makes continuous glucose monitoring genuinely accessible at $99 a month, with 15-day sensors and strong claimed accuracy — but the deliberately simple app and missing low-glucose alarms mark it out as a wellness tool, not a medical safety net.
Photo by Nutrisense Inc on Pexels
Abbott's over-the-counter Lingo turns proven FreeStyle Libre hardware into a gamified metabolic-health coach, and the roughly $50 two-week starter sensor makes it an unusually low-risk way to try a CGM. Accuracy is good rather than class-leading, and the app's spike-scoring may feel thin once the novelty fades.
Photo by Rafael Cerqueira on Pexels
Abbott's first over-the-counter CGM for non-insulin-using type 2 diabetes looks promising on paper — 15-day wear, a full 40-400 mg/dL range and no prescription — but it still isn't shipping, and with no price or accuracy data published, a firm verdict isn't possible yet.
Medtronic's first disposable, all-in-one CGM finally drags the company's sensor hardware into the modern era — smaller, faster to insert and free of overtape — but a 7-day wear life and 780G-only compatibility keep it a step behind rivals.
Photo by Pavel Danilyuk on Pexels
Medtronic's smallest, fully disposable CGM finally pairs a modern sensor with the InPen for people on multiple daily injections — a genuine leap over Guardian 4, though the closed ecosystem and unpublished pricing hold it back.
Photo by Nutrisense Inc on Pexels
The Abbott Lingo brings hassle-free, over-the-counter glucose tracking to general wellness seekers, though occasional connection dropouts can hold it back.
Kyverna Therapeutics says its CD19 CAR-T therapy miv-cel sustained clinical benefit and reversed disability through one year in the registrational KYSA-8 trial. If approved, it would be the first therapy for stiff person syndrome and the first CAR-T cleared for any autoimmune disease.
We use strictly necessary cookies to run this site, and optional analytics cookies only with your consent.
